Genmab A/S Stock

Genmab A/S Earnings Yield

The Earnings Yield of Genmab A/S (GMAB.CO) as of Aug 15, 2026 is 5.76 %. In the previous year, Earnings Yield was 6.80 % — a change of -15.35% (lower).

Earnings Yield

5.76 %

YoY

-15.35%

Last updated:

Earnings Yield of Genmab A/S is 2026 5.76 % . Earnings Yield of Genmab A/S was 2025 6.80 % . It decreases by -15.35% lower compared to the previous year.
Access this data via the Eulerpool API

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Earnings Yield of Genmab A/S is 5.76 % in 2026.

Earnings Yield of Genmab A/S changed from 6.80 % to 5.76 %, representing a -15.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Genmab A/S with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Genmab A/S

All Key Metrics — Genmab A/S